Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, today announces promising interim results ...

A hemorrhagic stroke, which makes up only about 13% of stroke cases, occurs when a blood vessel ruptures and bleeds into the ...

to treat intracerebral hemorrhagic stroke (ICH). Interim analysis from the first 16 patients in the standard-of-care controlled, randomized trial showed that primary safety and secondary efficacy ...

Gosselies, Belgium Saturday, April 26, 2025, 16:00 Hrs [IST] ...

The hypothesis that systolic blood pressure reduction in acute intracerebral hemorrhage increases the ... was funded by a grant from the Heart and Stroke Foundation of Canada.

Bioxodes SA is gearing up fundraising for a follow-up study to the newly released interim phase IIa results of its lead asset in preventing secondary damage after an intracerebral hemorrhagic stroke.

Primary endpoint met, no drug-related serious adverse eventsPositive hematoma and edema volume evolutionRecruitment stopped early due to positive exploratory and efficacy outcomesPreparations underway ...